ISLAND PHARMACEUTICALS LIMITED (ILA)
Share Price Analysis and Chart

11/02/2026

-1

No Rating

-2.38%

Island Pharmaceuticals has announced feedback from the US FDA on how to progress Galidesivir for approval under the Animal Rule pathway. The FDA provided guidance for regulatory alignment and this is considered a further de-risking event for the business as no more clarifying questions were required.

Pivotal study efficacy results are likely to be available in late 2026. Separately, the company has also raised $9m in a placement at $0.35 a share. It is now fully funded to complete the program and make its new drug submission.

It will become the first Australian biotech to deliver a drug by the Animal Rule pathway. Research as a Service (RaaS) provides a $1.24 valuation, raised from $1.14.

Research as a Service (RaaS) research doesn't carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

FORECAST
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.77 cents.
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -4.70 cents.